Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment.
The antihypertensive and renal haemodynamic effects of 5 mg/day tertatolol (T), a new nonselective and long-acting beta-adrenoceptor blocker, and 80 mg/day nadolol (N) in hypertensive patients with mild renal impairment have been compared in a randomized double-blind trial. Before and after 30 days of active treatment glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by use of a simultaneous i.v. bolus of 99mTc-DTPA and 131I-hippuran. Both T and N significantly decreased blood pressure and heart rate, and induced an insignificant increase in GFR and ERPF. There were no differences between the effect of the treatments on blood pressure and heart rate. Despite the persistent fall in BP and HR, renal function was maintained during both T or N treatment, suggesting that both drugs may act by a direct intrarenal vasodilator mechanism.
Institute of Semeiotica Medica, Roma, Italy.
F
F
Fallo
M
M
Gregianin
F
F
Bui
C
C
Macrì
P
P
Folino
F
F
Mantero
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects*; D009248:Nadolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D013876:Thiophenes
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D013876:Thiophenes; D009248:Nadolol; C005632:tertatolol